IGC Pharma, Inc. (IGC) revenue by segment
IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/3019% above fair value
$0.19+0.01 (+3.57%)
Close on Nov 18, 2026Market cap $20.12MP/E –Yield –
Doanh thu theo bộ phận của IGC Pharma, Inc.
Periods
Theo bộ phận kinh doanh
| Doanh thu | FY2025CY2024 | FY2024CY2023 | FY2023CY2022 | FY2022CY2021 | FY2021CY2020 | FY2020CY2019 | FY2019CY2018 | FY2018CY2017 | FY2017CY2016 | FY2016CY2015 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Legacy Infrastructure | – | – | – | $1.20M | – | – | $5.09M | $2.19M | – | – | – | – |
| Life Sciences | – | – | – | – | – | $411.00K | – | – | – | – | – | – |
| Plant and Cannabinoid | – | – | – | – | – | – | $25.00K | – | – | – | – | – |
Theo sản phẩm hoặc dịch vụ
| Doanh thu | FY2025CY2024 | FY2024CY2023 | FY2023CY2022 | FY2022CY2021 | FY2021CY2020 | FY2020CY2019 | FY2019CY2018 | FY2018CY2017 | FY2017CY2016 | FY2016CY2015 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plant and Cannabinoid | $1.27M | $1.35M | $798.00K | $359.00K | $723.00K | $411.00K | $25.00K | $0 | – | – | 100.0% | -5.5% |
| Life Sciences Segment | $1.27M | – | – | – | – | – | – | – | – | – | 100.0% | – |
| White Labeling Services | $1.16M | – | – | – | – | – | – | – | – | – | 91.1% | – |
| Tolling/White labeling service | $1.16M | $953.00K | $382.00K | $43.00K | $35.00K | – | – | – | – | – | 91.1% | +21.5% |
| Infrastructure Segment | $164.00K | – | – | – | – | – | – | – | – | – | 12.9% | – |
| Wellness and Lifestyle | $113.00K | $228.00K | $416.00K | $316.00K | $688.00K | – | – | – | – | – | 8.9% | -50.4% |
| Other Revenue | $0 | $164.00K | – | – | – | – | – | – | – | – | 0.0% | -100.0% |
| Legacy Infrastructure | – | $164.00K | $113.00K | $38.00K | $175.00K | $3.66M | $5.09M | $2.19M | – | – | – | – |
| Construction | – | $146.00K | $76.00K | $15.00K | $174.00K | $101.00K | – | – | – | – | – | – |
| Rental Income | – | $18.00K | $37.00K | $23.00K | $1.00K | – | – | – | – | – | – | – |
| Alternative Therapies | – | – | – | – | – | – | – | $0 | – | – | – | – |
| Legacy Business | – | – | – | – | – | – | – | $2.19M | – | – | – | – |
| Rental/Lease | – | – | – | – | – | – | – | – | $367.28K | $114.75K | – | – |
| Trading, electronic component | – | – | – | – | – | – | – | – | $213.09K | – | – | – |
| Trading | – | – | – | – | – | – | – | – | – | $6.25M | – | – |
Theo khu vực
| Doanh thu | FY2025CY2024 | FY2024CY2023 | FY2023CY2022 | FY2022CY2021 | FY2021CY2020 | FY2020CY2019 | FY2019CY2018 | FY2018CY2017 | FY2017CY2016 | FY2016CY2015 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.27M | $1.18M | $777.00K | $329.00K | – | – | – | $0 | – | – | 99.8% | +7.6% |
| Colombia | $2.00K | $2.00K | $21.00K | – | – | – | – | – | – | – | 0.2% | 0.0% |
| India | $0 | $164.00K | $113.00K | $68.00K | – | – | – | – | $124.87K | $114.75K | 0.0% | -100.0% |
| Asia | – | – | – | – | – | – | – | $395.44K | – | – | – | – |
| North America | – | – | – | $329.00K | $723.00K | $411.00K | $25.00K | $0 | – | – | – | – |
| Hong Kong SAR China | – | – | – | – | – | – | – | $1.80M | $213.09K | $6.25M | – | – |
| Malaysia | – | – | – | – | – | – | – | – | $242.41K | – | – | – |
Lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K, 10-Q của IGC Pharma (XBRL). Số quý 4 bằng cả năm tài chính trừ chín tháng đầu. Tên bộ phận giữ theo cách công ty tự đặt và có thể đổi khi công ty tái cấu trúc. Tab KPI hiện các bộ phận này cạnh chỉ số vận hành của IGC Pharma, kèm đầy đủ lịch sử, biểu đồ và liên kết tới từng hồ sơ.
See a number that looks wrong?